Shares of Nevro (NVRO) Sees Large Inflow of Net Money Flow

Nevro (NVRO) : Mondays money flow data in Nevro (NVRO) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $3.69 million, whereas, $2.17 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.7, in favor of the bulls. The total money flow into the stock was $1.52 million clearly indicating that the smart money has been buying into the stock on weakness.

In comparison, the money flow in block deals was $2.41 million. The total value of block trades done on upticks was $2.41 million. Nevro (NVRO) fell $0.68 and traded at $79.78, down -0.85% for the day, over previous days close. On a weekly basis, the shares are 1.94% over the previous weeks close.


Nevro Corp. is up 16.14% in the last 3-month period. Year-to-Date the stock performance stands at 18.52%. Shares of Nevro Corp. rose by 0.59% in the last five trading days and 10.71% for the last 4 weeks. In a related news, The Securities and Exchange Commission has divulged that Alleavitch Doug, officer (VP, Quality) of Nevro Corp, had unloaded 2,000 shares at an average price of $80 in a transaction dated on July 11, 2016. The total value of the transaction was worth $160,000.

Nevro (NYSE:NVRO): On Mondays trading session , Opening price of the stock was $80.57 with an intraday high of $80.87. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $79.46. However, the stock managed to close at $80.01, a loss of 0.56% for the day. On the previous day, the stock had closed at $80.46. The total traded volume of the day was 315,563 shares.

Nevro Corp. is a medical device company. The Company manufactures and markets active implantable medical devices for the treatment of neurological disorders initially focusing on the treatment of chronic pain. The Company developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Companys Senza system is the only spinal cord stimulation (SCS) system that delivers its HF10 therapy. The Companys Senza system creates electrical impulses from two hertz to 10 kilohertz, including its HF10 therapy, which allows for pain relief without paresthesia. HF10 therapy delivers waveforms at 10 kilohertz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *